PsyBio continues towards understanding psycho-targeted, biosynthesized tryptamines and remains strongly committed to innovation, development, and technology optimization demonstrated by the desire to advance compounds into clinical trials OXFORD, OH and DENVER, CO, Oct. 11, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“)…


Previous articlePT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of Legality Inside an Endless Drug War
Next articleClearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV